E
Evan Appelbaum
Researcher at Beth Israel Deaconess Medical Center
Publications - 71
Citations - 6035
Evan Appelbaum is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Hypertrophic cardiomyopathy & Cardiomyopathy. The author has an hindex of 29, co-authored 69 publications receiving 5315 citations. Previous affiliations of Evan Appelbaum include Beth Israel Deaconess Hospital & Harvard University.
Papers
More filters
Journal ArticleDOI
Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy
Raymond H. Chan,Barry J. Maron,Iacopo Olivotto,Michael J. Pencina,Gabriele Egidy Assenza,Tammy S. Haas,John R. Lesser,Christiane Gruner,Andrew M. Crean,Harry Rakowski,James E. Udelson,Ethan J. Rowin,Massimo Lombardi,Franco Cecchi,Benedetta Tomberli,Paolo Spirito,Francesco Formisano,Elena Biagini,Claudio Rapezzi,Carlo N. De Cecco,Camillo Autore,E. Francis Cook,Susie N. Hong,C. Michael Gibson,Warren J. Manning,Evan Appelbaum,Martin S. Maron +26 more
TL;DR: Extensive LGE measured by quantitative contrast enhanced CMR provides additional information for assessing SCD event risk among HCM patients, particularly patients otherwise judged to be at low risk.
Journal ArticleDOI
Occurrence and Frequency of Arrhythmias in Hypertrophic Cardiomyopathy in Relation to Delayed Enhancement on Cardiovascular Magnetic Resonance
A. Selcuk Adabag,Barry J. Maron,Evan Appelbaum,Evan Appelbaum,Caitlin J. Harrigan,Jacqueline L. Buros,C. Michael Gibson,C. Michael Gibson,John R. Lesser,Constance A. Hanna,James E. Udelson,Warren J. Manning,Warren J. Manning,Martin S. Maron +13 more
TL;DR: In this large HCM cohort with no or only mild symptoms, myocardial fibrosis detected by CMR was associated with greater likelihood and increased frequency of ventricular tachyarrhythmias (including NSVT) on ambulatory Holter ECG.
Journal ArticleDOI
Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney Disease: The PRIMO Randomized Controlled Trial
Ravi Thadhani,Evan Appelbaum,Yili Pritchett,Yuchiao Chang,Julia Wenger,Hector Tamez,Ishir Bhan,Rajiv Agarwal,Carmine Zoccali,Christoph Wanner,Donald M. Lloyd-Jones,J.B. Cannata,B. Taylor Thompson,Dennis L. Andress,Wuyan Zhang,David K. Packham,David K. Packham,Bhupinder Singh,Daniel Zehnder,Amil M. Shah,Ajay Pachika,Warren J. Manning,Scott D. Solomon +22 more
Abstract: Context Vitamin D is associated with decreased cardiovascular-related morbidity and mortality, possibly by modifying cardiac structure and function, yet firm evidence for either remains lacking. Objective To determine the effects of an active vitamin D compound, paricalcitol, on left ventricular mass over 48 weeks in patients with an estimated glomerular filtration rate of 15 to 60 mL/min/1.73 m 2 . Design, Setting, and Participants Multinational, double-blind, randomized placebo-controlled trial among 227 patients with chronic kidney disease, mild to moderate left ventricular hypertrophy, and preserved left ventricular ejection fraction, conducted in 11 countries from July 2008 through September 2010. Intervention Participants were randomly assigned to receive oral paricalcitol, 2 μg/d (n =115), or matching placebo (n = 112). Main Outcome Measures Change in left ventricular mass index over 48 weeks by cardiovascular magnetic resonance imaging. Secondary end points included echocardiographic changes in left ventricular diastolic function. Results Treatment with paricalcitol reduced parathyroid hormone levels within 4 weeks and maintained levels within the normal range throughout the study duration. At 48 weeks, the change in left ventricular mass index did not differ between treatment groups (paricalcitol group, 0.34 g/m 2.7 [95% CI, −0.14 to 0.83 g/m 2.7 ] vs placebo group, −0.07 g/m 2.7 [95% CI, −0.55 to 0.42 g/m 2.7 ]). Doppler measures of diastolic function including peak early diastolic lateral mitral annular tissue velocity (paricalcitol group, −0.01 cm/s [95% CI, −0.63 to 0.60 cm/s] vs placebo group, −0.30 cm/s [95% CI, −0.93 to 0.34 cm/s]) also did not differ. Episodes of hypercalcemia were more frequent in the paricalcitol group compared with the placebo group. Conclusion Forty-eight week therapy with paricalcitol did not alter left ventricular mass index or improve certain measures of diastolic dysfunction in patients with chronic kidney disease. Trial Registration clinicaltrials.gov Identifier: NCT00497146
Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney Disease
Ravi Thadhani,Evan Appelbaum,Yili Pritchett,Julia Wenger,Hector Tamez,Ishir Bhan,Rajiv Agarwal,Carmine Zoccali,Christoph Wanner,Donald M. Lloyd-Jones,J.B. Cannata,B. Taylor Thompson,Dennis L. Andress,Wuyan Zhang,David K. Packham,Bhupinder Singh,Daniel Zehnder,Amil M. Shah,Warren J. Manning,Scott D. Solomon +19 more
TL;DR: Forty-eight week therapy with paricalcitol did not alter left ventricular mass index or improve certain measures of diastolic dysfunction in patients with chronic kidney disease.
Journal ArticleDOI
Hypertrophic Cardiomyopathy Phenotype Revisited After 50 Years With Cardiovascular Magnetic Resonance
Martin S. Maron,Barry J. Maron,Caitlin J. Harrigan,Jacki Buros,C. Michael Gibson,C. Michael Gibson,Iacopo Olivotto,Leah H. Biller,John R. Lesser,James E. Udelson,Warren J. Manning,Warren J. Manning,Evan Appelbaum,Evan Appelbaum +13 more
TL;DR: Patterns of LV hypertrophy are usually not extensive in HCM, involving < or = 50% of the chamber in about one-half the patients, and are particularly limited in extent in an important minority, which supports an emerging role for CMR in the contemporary evaluation of patients with HCM.